期刊
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
卷 308, 期 13, 页码 1340-1349出版社
AMER MEDICAL ASSOC
DOI: 10.1001/jama.2012.12559
关键词
-
资金
- sanofi-aventis
- Servier [U-698]
- New York University School of Medicine
- Ablynx
- Amarin
- Amgen
- Astellas
- AstraZeneca
- Bayer
- Boehringer Ingelheim
- Bristol-Meyers Squibb
- Daiichi Sankyo
- Eisai
- GlaxoSmithKline
- Lilly
- Medtronic
- Merck Sharp Dohme
- Novartis
- Otsuka
- Pfizer
- Roche
- Medicines Company
- Forest Pharmaceuticals
- Daichii Sankyo
- Asteras
- Medtronics Japan
- Mitsubishi Tanabe
- Takeda
- Mochida
- Eli Lilly Company
- Maquet
- Accumetrics
- Essentials
- Merck
- Regeneron
- Ethicon
- Waksman Foundation (Tokyo, Japan)
- Grants-in-Aid for Scientific Research [24390202] Funding Source: KAKEN
Context beta-Blockers remain the standard of care after a myocardial infarction (MI). However, the benefit of beta-blocker use in patients with coronary artery disease (CAD) but no history of MI, those with a remote history of MI, and those with only risk factors for CAD is unclear. Objective To assess the association of beta-blocker use with cardiovascular events in stable patients with a prior history of MI, in those with CAD but no history of MI, and in those with only risk factors for CAD. Design, Setting, and Patients Longitudinal, observational study of patients in the Reduction of Atherothrombosis for Continued Health (REACH) registry who were divided into 3 cohorts: known prior MI (n = 14 043), known CAD without MI (n = 12 012), or those with CAD risk factors only (n = 18 653). Propensity score matching was used for the primary analyses. The last follow-up data collection was April 2009. Main Outcome Measures The primary outcome was a composite of cardiovascular death, nonfatal MI, or nonfatal stroke. The secondary outcome was the primary outcome plus hospitalization for atherothrombotic events or a revascularization procedure. Results Among the 44 708 patients, 21 860 were included in the propensity score-matched analysis. With a median follow-up of 44 months (interquartile range, 35-45 months), event rates were not significantly different in patients with beta-blocker use compared with those without beta-blocker use for any of the outcomes tested, even in the prior MI cohort (489 [16.93%] vs 532 [18.60%], respectively; hazard ratio [HR], 0.90 [95% CI, 0.79-1.03]; P = .14). In the CAD without MI cohort, the associated event rates were not significantly different in those with beta-blocker use for the primary outcome (391 [12.94%]) vs without beta-blocker use (405 [13.55%]) (HR, 0.92[95% CI, 0.79-1.08]; P = .31), with higher rates for the secondary outcome (1101 [30.59%] vs 1002 [27.84%]; odds ratio [OR], 1.14 [95% CI, 1.03-1.27]; P = .01) and for the tertiary outcome of hospitalization (870 [24.17%] vs 773 [21.48%]; OR, 1.17 [95% CI, 1.04-1.30]; P = .01). In the cohort with CAD risk factors only, the event rates were higher for the primary outcome with beta-blocker use (467 [14.22%]) vs without beta-blocker use (403 [12.11%]) (HR, 1.18 [95% CI, 1.02-1.36]; P = .02), for the secondary outcome (870 [22.01%] vs 797 [20.17%]; OR, 1.12 [95% CI, 1.00-1.24]; P = .04) but not for the tertiary outcomes of MI (89 [2.82%] vs 68 [2.00%]; HR, 1.36 [95% CI, 0.97-1.90]; P = .08) and stroke (210 [6.55%] vs 168 [5.12%]; HR, 1.22 [95% CI, 0.99-1.52]; P = .06). However, in those with recent MI (<= 1 year), beta-blocker use was associated with a lower incidence of the secondary outcome (OR, 0.77 [95% CI, 0.64-0.92]). Conclusion In this observational study of patients with either CAD risk factors only, known prior MI, or known CAD without MI, the use of beta-blockers was not associated with a lower risk of composite cardiovascular events. JAMA. 2012;308(13):1340-1349
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据